Get started
Author

Bernadette A. Redd

Automated abnormality classification of chest radiographs using deep convolutional neural networks
2020 · Yu-Xing Tang, Yu-Xing Tang, et al. · npj Digital Medicine · 248
PDF
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
2020 · Changqing Xie, Austin G. Duffy, et al. · Clinical Cancer Research · 101
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
2023 · Cecilia Monge, Changqing Xie, et al. · Journal for ImmunoTherapy of Cancer · 75
PDF
Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer
2024 · Amy E. Turriff, Christina M. Annunziata, et al. · New England Journal of Medicine · 48
PDF
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
2024 · Elena Giudice, Tzu-Ting Huang, et al. · Nature Communications · 48
PDF
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma
2022 · Cecilia Monge, Erica C Pehrsson, et al. · The Oncologist · 43
PDF
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors
2024 · Andrea B. Apolo, Daniel M. Girardi, et al. · Journal of Clinical Oncology · 28
PDF
Consensus-driven conceptual development of a standardized whole body-MRI scoring system for assessment of disease activity in juvenile idiopathic arthritis: MRI in JIA OMERACT working group
2021 · Jyoti Panwar, Mirkamal Tolend, et al. · Seminars in Arthritis and Rheumatism · 27
PDF
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab
2025 · Yuta Myojin, Sepideh Babaei, et al. · Gut · 23
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).
2023 · Changqing Xie, M. Cecilia Monge B., et al. · Journal of Clinical Oncology · 19
The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee
2024 · Valeria Panebianco, Alberto Briganti, et al. · European Urology · 17
PDF
Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study
2024 · Maria Mironova, Harish Gopalakrishna, et al. · Alimentary Pharmacology & Therapeutics · 13
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma
2024 · Cecilia Monge, Changqing Xie, et al. · Cancer Medicine · 13
PDF
Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee
2025 · Valeria Panebianco, Alberto Briganti, et al. · European Urology · 12
Comparison of CT and Dixon MR Abdominal Adipose Tissue Quantification Using a Unified Computer-Assisted Software Framework
2023 · Li-Yueh Hsu, Zara Ali, et al. · Tomography · 12
PDF
VI-RADS quality score: development and proposal of a scoring system by the American College of Radiology VI-RADS Steering Committee
2025 · Sungmin Woo, Lyndon Luk, et al. · European Radiology · 11
PDF
SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.
2024 · Andre Rashad Kydd, Elias Chandran, et al. · Journal of Clinical Oncology · 11
VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial
2024 · Kelley Coffman-D'Annibale, Yuta Myojin, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics
2023 · Lauren A. Gamble, Paul H. McClelland, et al. · npj Breast Cancer · 9
PDF
A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) – design and rationale
2025 · Andre R. Kydd, Elias Chandran, et al. · Future Oncology · 7
A phase I/II study of JX-594 oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer
2020 · C. Monge, C. Xie, et al. · European Journal of Cancer · 7
PDF
Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers
2025 · Chi Ma, Joy A. Awosika, et al. · Cancer Letters · 5
Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management
2025 · Nicholas I Simon, Andre R Kydd, et al. · Bladder Cancer · 4
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale
2025 · Elias B. A. Chandran, Saad Atiq, et al. · Future Oncology · 4
Reliability assessment of the OMERACT whole-body magnetic resonance imaging scoring system for juvenile idiopathic arthritis
2024 · Jyoti Panwar, Mirkamal Tolend, et al. · Seminars in Arthritis and Rheumatism · 4
Works count: 92
Citation count: 817
H-index: 13
I10-index: 18
Year
Topic
Type